Insilico Medicine completed a Hong Kong initial public offering as the AI‑driven drug discovery firm went public after four years of attempted listings. The company, one of the pioneers in applying generative and predictive AI to small‑molecule discovery, raised gross proceeds in the offering and said the IPO strengthens its capital position for advancing preclinical and clinical programs. The listing underscores investor appetite for AI‑native drug developers despite a choppy financing backdrop for life‑science tools.